GEN Exclusives

More »

GEN News Highlights

More »
Mar 29, 2007

Evotec Strengthens CNS Pipeline with Neuro3d Acquisition

  • Evotec plans to enhance its focus on drugs targeting the central nervous system (CNS) through the stock-for-stock acquisition of Neuro3d. The company reports that it thus has access to Neuro3d’s assays and know-how about a target that has potential for the treatment of a number of diseases of the CNS and a related focused compound library.

    Evotec also gains Neuro3d’s Euro 22 million of net cash. Of this amount, approximately Euro 18 million of cash are included in Neuro3d’s balance sheet already, and the remainder is expected to be received by the beginning of 2009.

    The net cash proceeds from this transaction will be used to advance the acquired CNS project and to expand Evotec’s preclinical discovery efforts with the goal to further strengthen its CNS pipeline, according to the company.



GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »